A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
Viruses · 24.01.2025 · 17 (2) · 163
DOI: 10.3390/v17020163 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 24.01.2025. Verfasst von Lorenza Di Marco und 8 weiteren Autor:innen. Beteiligte Einrichtung: SIcilian Network for Therapy, Epidemiology and Screening In Hepatology (SINTESI), 90127 Palermo, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Hepacivirus, Interferons, Hepatitis C. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The treatment landscape for hepatitis C virus (HCV) infection has transformed over the past few decades, evolving from the limited efficacy of interferon (IFN) monotherapy to the highly successful pan-genotypic direct-acting antivirals (DAAs) used today. Initially, alpha-interferon monotherapy, introduced in the 1990s, was the standard treatment, yet it provided low sustained virological response (SVR) rates and caused significant adverse effects, limiting its utility. The development of pegylated interferon (peg-IFN) improved the pharmacokinetic profile of IFN, allowing for less frequent dosing and modestly improved response rates. When combined with ribavirin, peg-IFN achieved higher SVR rates, especially in non-genotype 1 HCV infections, but the combination also brought additional side effects, such as anemia and depression. The advent of the first-generation DAAs, such as telaprevir and boceprevir, marked a significant milestone. Combined with peg-IFN and ribavirin, these protease inhibitors boosted response rates in patients with genotype 1 HCV. However, high rates of adverse effects and drug resistance remained challenges. Second-generation DAAs, like sofosbuvir and ledipasvir, introduced IFN-free regimens with improved safety profiles and efficacy. The most recent advances are pan-genotypic DAAs, including glecaprevir-pibrentasvir and sofosbuvir-velpatasvir, which offer high SVR rates across all genotypes, shorter treatment durations, and fewer side effects. Current pan-genotypic regimens represent a cornerstone in HCV therapy, providing an accessible and effective solution globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SIcilian Network for Therapy, Epidemiology and Screening In Hepatology (SINTESI), 90127 Palermo, Italy.
- Department of Oncology and Hematology, Azienda Ospedaliero-University Hospital of Mod, 41124 Modena, Italy.
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41100 Modena, Italy.
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.
- Department of Medicine, Buccheri-La Ferla Hospital, 90123 Palermo, Italy.
ORCID-Profile: Lorenza Di Marco, Vincenza Calvaruso
Zitieren
APA
Di Marco, L., Cannova, S., Ferrigno, E., Landro, G., Nonni, R., Mantia, C., Cartabellotta, F., Calvaruso, V., & Di Marco, V. (2025). A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs). Viruses, 17(2), 163. https://doi.org/10.3390/v17020163
Vancouver
Di Marco L, Cannova S, Ferrigno E, Landro G, Nonni R, Mantia C, et al. A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs). Viruses. 2025;17(2):163. doi:10.3390/v17020163
BibTeX
@article{DiMarco2025,
author = {Di Marco, Lorenza and Cannova, Simona and Ferrigno, Emanuele and Landro, Giuseppe and Nonni, Rosario and Mantia, Claudia La and Cartabellotta, Fabio and Calvaruso, Vincenza and Di Marco, Vito},
title = {A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)},
journal = {Viruses},
year = {2025},
volume = {17},
number = {2},
pages = {163},
doi = {10.3390/v17020163}
}
EUVIMED